Psoriatic Disease News

The National Psoriasis Foundation has announced the honorees for this year’s Commit to Cure Gala, according to a press release.

Blue-collar workers with psoriatic arthritis demonstrate an increased risk for work disability vs. white-collar workers with the same disease, according to data published in Clinical Rheumatology.

Infliximab biosimilar uptake increased by no more than just 5% annually following the release of its first two biosimilars, but then shot up by 13% to 16% for most patients after a third option emerged, according to data.

Artax Biopharma has recruited all 30 patients to a phase 2a clinical trial of AX-158, its investigative Nck modulator for autoimmune diseases, the company announced in a press release.

The National Psoriasis Foundation dedicated August to psoriasis education, awareness and education, designating it Psoriasis Action Month.

Tildrakizumab exhibited real-world efficacy and safety for long-term treatment of plaque psoriasis, according to a study.

In September 2022, the FDA approved deucravacitinib for moderate-to-severe plaque psoriasis, officially introducing tyrosine kinase 2 inhibition to clinics across the United States.

The list prices of Stelara and Enbrel for Medicare users will be discounted nearly 70% come 2026 as a result of the first round CMS price negotiations with drugmakers, the White House has announced.

The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.